#USA #Minneapolis #Bio-Techne #stem cell #Cultrex Synthetic

Bio-Techne Introduces Cultrex Synthetic Hydrogel for 3D Stem Cell Research

In a significant advancement for life sciences, Bio-Techne Corporation (NASDAQ: TECH) has officially launched its latest product, the Cultrex Synthetic Hydrogel. This innovative extracellular matrix (ECM) is fully defined and synthesized to meet the rising demands of reproducible and scalable 3D stem cell and organoid research. Amidst the changing landscape of biomedical research, this product is set to enhance the consistency and reliability of experimental outcomes.

Addressing Research Challenges

Bio-Techne's latest offering is designed to address critical challenges faced by researchers. Traditional matrices used for 3D stem cell cultures often suffer from lot-to-lot variability, creating discrepancies in experimental results that can hinder research advancement. The Cultrex Synthetic Hydrogel is specifically engineered to mitigate these issues, thereby providing a more stable platform for diverse applications such as drug screening, toxicology, and personalized medicine.

By providing a synthetic alternative to traditional ECMs, the Cultrex Hydrogel not only avoids the biological variabilities but also aligns with the FDA's ongoing initiatives to improve translational research outcomes. This is particularly relevant as the pharmaceutical industry increasingly turns to new approach methodologies (NAMs) that emphasize reproducibility and thus, innovation in research practices.

Benefits of Synthetic Solutions

The use of the Cultrex Synthetic Hydrogel transcends mere reproducibility; it offers a compelling case for the broader adoption of organoid models. With its controlled composition, the hydrogel enables researchers to standardize experimental conditions across different laboratories, which plays a pivotal role in enhancing the overall quality of research data. The launch represents a step forward for scientists who are pursuing FDA-regulatory aspects in preclinical studies, and the hydrogel provides a reliable means of traceability as research progresses.

Will Geist, President of the Protein Sciences Segment at Bio-Techne, expressed that this product reflects the increasingly sophisticated needs of researchers: "Cultrex Synthetic Hydrogel expands our Cultrex ECM portfolio with a fully defined, scalable option that supports reproducibility and consistency as programs mature, without compromising the performance that researchers expect."

Comprehensive Portfolio Expansion

This new product is part of Bio-Techne's ongoing commitment to innovating solutions for stem cell and organoid culture. The Cultrex Synthetic Hydrogel is set to complement existing offerings such as Cultrex Basement Membrane Extracts (BME), along with recombinant cytokines and growth factors, AI-modified proteins, and essential media and supplements for research flexibility. Researchers now have the option to select ECM solutions tailored to their specific experimental protocols and compatibility with regulatory guidelines.

For those interested in learning more about the Cultrex Synthetic Hydrogel or to explore Bio-Techne’s full range of products, visiting their official website is recommended. With net sales of over $1.2 billion for the fiscal year 2025 and a workforce of approximately 3,100 employees worldwide, Bio-Techne continues to serve as a pioneer in the realms of scientific research and clinical diagnostics.

In conclusion, Bio-Techne’s Cultrex Synthetic Hydrogel marks a revolutionary step in the domain of stem cell research, promising to establish greater consistency, reproducibility, and alignment with regulatory demands—a much-needed advancement in contemporary biomedicine.